Preclinical PK/PD modeling and human efficacious dose projection for a glucokinase activator in the treatment of diabetes

Author： Zager Michael   Kozminski Kirk   Pascual Bernadette   Ogilvie Kathleen   Sun Shaoxian  

Publisher： Springer Publishing Company

ISSN： 1567-567X

Source： Journal of Pharmacokinetics and Pharmacodynamics, Vol.41, Iss.2, 2014-04, pp. : 127-139

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Translational PK-PD modeling in pain

By Yassen Ashraf  

Journal of Pharmacokinetics and Pharmacodynamics, Vol. 40, Iss. 3, 2013-06 ,pp. : 401-418

Springer Publishing Company

Access to resources Recommend Favorite

A Bayesian Approach for PK/PD Modeling with PD Data Below Limit of Quantification

By Zhou Huafeng  

Journal of Biopharmaceutical Statistics, Vol. 22, Iss. 6, 2012-11 ,pp. : 1220-1243

Taylor & Francis Ltd

Access to resources Recommend Favorite

Quantitative systems pharmacology as an extension of PK/PD modeling in CNS research and development

By Geerts Hugo  

Journal of Pharmacokinetics and Pharmacodynamics, Vol. 40, Iss. 3, 2013-06 ,pp. : 257-265

Springer Publishing Company

Access to resources Recommend Favorite

Emtricitabine/tenofovir in the treatment of HIV infection: current PK/PD evaluation

By Uglietti Alessia   Zanaboni Domenico   Gnarini Mariarosaria   Maserati Renato  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 8, Iss. 10, 2012-10 ,pp. : 1305-1314

Informa Healthcare

Access to resources Recommend Favorite

Preclinical Drug Metabolism and Pharmacokinetics, and Prediction of Human Pharmacokinetics and Efficacious Dose of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237)

By  

Drug Metabolism Letters, Vol. 7, Iss. 2, 2014-05 ,pp. : 96-104

Bentham Science Publishers

Access to resources Recommend Favorite